Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,858 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06397963Recruiting
Personalized immune cell therapy for advanced solid tumors
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Beijing, Beijing MunicipalityAges 18–70 - NCT06934538RecruitingPhase 1/Phase 2
Immunotherapy trial for advanced colorectal cancer
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Baltimore, MarylandAges 18–75 - NCT06504368RecruitingPhase 1
Testing a new drug DCR-PDL1 for advanced solid tumors
This trial tests an experimental drug called DCR-PDL1 for people with advanced solid tumors or non-Hodgkin's lymphoma that has not responded to, progressed on, or could not tolerate standard treatments, or for which no standard treatment exists. The goal is to see if it is safe and how the body processes it.
Irving, TexasAges 18 years+ - NCT06265727RecruitingPhase 1/Phase 2
Study of CRB-701 for solid tumors with nectin-4
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
Birmingham, AlabamaAges 18 years+ - NCT07016490RecruitingPhase 1
Study of SSGJ-709 for advanced solid tumors
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
AdelaideAges 18 years+ - NCT06477614RecruitingPhase 1
Personalized vaccine for advanced solid tumors
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help your body fight advanced cancer. It is for people whose cancer has not responded to other treatments.
Guanzhou, GuangdongAges 18–80 - NCT06600022RecruitingPhase 1/Phase 2
Studying SCTB41 for advanced solid tumors
This trial tests a new drug called SCTB41 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it shrinks tumors.
Guangzhou, GuangdongAges 18 years+ - NCT07179081RecruitingPhase 1
Study of AL58805 for advanced cancers
This trial is testing a new drug called AL58805 for people with advanced cancers that have not improved with standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
Changsha, HunanAges 18 years+ - NCT06963281RecruitingPhase 1
Study of an experimental drug for late-stage solid tumors
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
Pheonix, ArizonaAges 18–75 - NCT07390383RecruitingPhase 2
LBL-024 combo for advanced gastric cancer
This trial tests a new combination drug called LBL-024 in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the treatment can help shrink the tumor or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06241898RecruitingPhase 1
First study of a new drug for advanced solid tumors
This study tests a new drug (BB-1709) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it's safe and how well it works.
Beijing, Beijing MunicipalityAges 18–78 - NCT07389733RecruitingPhase 1/Phase 2
Study of HRS-6208 with other drugs for advanced breast cancer
This trial tests a new combination of drugs (HRS-6208 with HRS-8080, fulvestrant, or letrozole) for people with advanced or metastatic breast cancer that cannot be removed by surgery. It aims to see if these combinations can help shrink or slow the cancer.
Dalian, LiaoningAges 18–75 - NCT06563375RecruitingPhase 1
Testing NP-101 for advanced solid tumors
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
Houston, TexasAges 18 years+ - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Orange, CaliforniaAges 18 years+ - NCT07359820RecruitingPhase 2
Lirafugratinib for solid tumors with FGFR2 fusion
This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.
Phoenix, ArizonaAges 18 years+ - NCT05579275RecruitingEarly Phase 1
Study JCXH-212 to treat advanced solid tumors safely
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
Beijing, Beijing MunicipalityAges 18–75 - NCT07319130Enrolling by invitation
Testing a new PET scan for Nectin-4-positive tumors
This trial tests a new imaging injection (a radioactive tracer called 68Ga) that sticks to a protein called Nectin-4, which is often found on cancer cells. The goal is to see if this scan can better find tumors in people with certain solid cancers, such as bladder, breast, or lung cancer.
Suzhou, JiangsuAges 18 years+ - NCT05868876RecruitingPhase 1
Testing AK127 plus AK104 for advanced cancers
This Phase 1 study tests the safety and early anti-cancer activity of AK127 given together with AK104 in people with advanced solid tumors. You may be considered if standard treatments have already been tried or aren’t suitable for you.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07288957RecruitingPhase 1
Testing ABSK131 for advanced solid tumors with a specific genetic change
This trial tests a new drug called ABSK131 in people whose cancer has a missing MTAP gene. It is for advanced solid tumors that have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07274813RecruitingEarly Phase 1
Study of HLX37 for advanced solid tumors that haven't responded to treatment
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
ShanghaiAges 18–75 - NCT06908434RecruitingPhase 1
GenSci128 for solid tumors with TP53 Y220C mutation
This trial tests a new drug, GenSci128, for people whose solid tumors have a specific TP53 Y220C mutation. The drug aims to reactivate the p53 protein to fight cancer. It is for patients who have exhausted standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06885281RecruitingPhase 1/Phase 2
Study of ZL-1310 for neuroendocrine carcinoma
This trial is testing an experimental drug called ZL-1310 for people with neuroendocrine carcinoma (a rare, fast-growing cancer) that has spread or can't be removed. It aims to see if the drug is safe and works against the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06375564RecruitingPhase 1
A new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (177Lu-AB-3PRGD2) that targets a protein called integrin αvβ3 found on many solid tumors. It is for people whose cancer has not responded to or has come back after several standard treatments.
Xiamen, FujianAges 18–90 - NCT07205198RecruitingPhase 1
Study of SIBP-A10 for advanced solid tumors
This trial tests a new drug called SIBP-A10 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug is safe and helps shrink tumors.
Dalian, LiaoningAges 18–75
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,858 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.